AR Expression Correlates with Distinctive Clinicopathological and Genomic Features in Breast Cancer Regardless of ESR1 Expression Status

Mengping Long, Chong You, Qianqian Song, Lina X. J. Hu, Zhaorong Guo, Qian Yao, Wei Hou, Wei Sun, Baosheng Liang, Xiao‐Hua Zhou, Yiqiang Liu, Taobo HuInternational Journal of Molecular Sciences 2022 · DOI

TL;DR

This study investigates the role of Androgen Receptor (AR) in breast cancer, particularly its distinct behavior in Estrogen Receptor (ER)-positive versus ER-negative tumors. The research reveals that AR expression is linked to different clinicopathological and molecular features depending on ER status, suggesting AR plays a context-dependent role in breast cancer progression and treatment.

What Problem Does This Paper Address?

Breast cancer is a complex disease with various subtypes, and understanding the molecular drivers of each is crucial for effective treatment. While Estrogen Receptor (ER) is a well-established target, the role of Androgen Receptor (AR) is less clear, especially its interplay with ER. AR is frequently found in breast cancer, but its association with ER expression and its impact on tumor characteristics and prognosis remain poorly understood. This paper aims to clarify these relationships by analyzing AR expression in conjunction with ER status and examining the resulting clinicopathological and genomic differences.

Methods

The study employed a multi-pronged approach:

  • Immunohistochemistry (IHC): This standard technique was used to assess the expression levels of AR, ER, PR, HER2, and Ki67 in tumor samples from the Peking University Cancer Hospital (PKUCH) cohort.
  • Statistical Analysis: Clinicopathological characteristics were compared between AR-positive and AR-negative groups within both ER-positive and ER-negative patient cohorts using statistical tests like Kruskal-Wallis and chi-squared tests.
  • Bioinformatics Analysis: Publicly available datasets from The Cancer Genome Atlas (TCGA) and the Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) were utilized. RNA-sequencing data was analyzed to identify differentially expressed genes (DEGs) between AR-high and AR-low groups in both ER-positive and ER-negative breast cancers. Pathway enrichment analysis (using ReactomePA) was performed on these DEGs to understand the biological processes affected by AR expression.

Datasets

  • PKUCH Cohort: A local cohort of 323 invasive breast carcinoma cases diagnosed at Peking University Cancer Hospital between September 2019 and May 2021. These samples were used for IHC analysis and clinicopathological comparisons.
  • TCGA (The Cancer Genome Atlas): RNA-seq and clinical data from 1102 breast cancer samples were used for DEG analysis.
  • METABRIC (Molecular Taxonomy of Breast Cancer International Consortium): RNA expression and clinical data from 1904 breast cancer samples were used for DEG analysis.

Key Insights and Ideas

  • Context-Dependent Role of AR: The most significant insight is that AR's role in breast cancer is not monolithic. Its association with tumor features and molecular pathways differs substantially between ER-positive and ER-negative breast cancers. This highlights the need for personalized treatment strategies that consider the ER status.
  • AR Negativity as a Marker of Aggression in ER-Negative Cancers: The study found that AR-negative ER-negative breast cancers exhibited poorer clinicopathological features, including a higher Ki67 proliferation index, suggesting AR might act as a protective factor or a marker of less aggressive disease in this subtype.
  • Distinct Molecular Signatures: The analysis of DEGs revealed that AR regulates different sets of genes and pathways in ER-positive versus ER-negative breast cancers. This suggests fundamentally different molecular mechanisms are at play, further supporting the context-dependent role of AR.
  • Potential for AR-Targeted Therapies: While the study doesn't directly test therapies, understanding these distinct molecular roles could pave the way for more targeted AR-based treatments, especially in ER-negative breast cancers where AR antagonists have shown some promise.

Key Results

  • AR Expression Prevalence: AR was expressed in a high percentage of ER-positive breast cancers (92%) and a notable portion of ER-negative breast cancers (47%) in the PKUCH cohort.
  • Clinicopathological Differences:
    • In ER-positive breast cancer, AR negativity was associated with PR negativity.
  • In ER-negative breast cancer, AR-negative tumors were linked to older age at diagnosis and a less advanced histologic grade.
  • The Ki67 proliferation index was significantly higher in AR-negative ER-negative breast cancer compared to AR-positive ER-negative breast cancer.
  • Genomic Differences:
    • In ER-positive breast cancer, 6 shared DEGs were identified between AR-high and AR-low groups, enriched in pathways like steroid hormone synthesis and EGFR activation.
  • In ER-negative breast cancer, 55 shared DEGs were identified, enriched in pathways related to cell metabolism and ER regulation. Notably, no shared pathways were found between the ER-positive and ER-negative DEG analyses, emphasizing the distinct molecular mechanisms.

Limitations and Future Work

  • Retrospective Study: The PKUCH cohort was retrospective, lacking survival information. This prevents the investigation of the prognostic value of AR negativity in different ER contexts.
  • HER2-Negative Focus: The study primarily focused on HER2-negative breast cancer. Previous research suggests AR pathway activity can differ in HER2-positive and HER2-negative cancers, so this limitation might affect generalizability.
  • Confounding Factors: The retrospective nature also means a lack of information on potential confounding factors like smoking, body mass index, and reproductive history, which could influence results.
  • Future Directions: The authors emphasize the need for further characterization of the altered pathways and molecular features associated with AR expression in both ER-positive and ER-negative breast cancers. This is crucial for the precise application of AR-targeted therapies. Investigating the prognostic value of AR negativity in larger, prospective cohorts is also a key next step.

Summary updated

Abstract

Androgen receptor (AR) expression is frequently observed in breast cancer, but its association with estrogen receptor (ER) expression in breast cancer remains unclear. This study analyzed the clinicopathological and molecular features associated with AR negativity in both ER-positive and ER-negative breast cancer, trying to elucidate the molecular correlation between AR and ER. Our results showed that AR negativity was associated with different clinicopathological characteristics and molecular features in ER-positive and ER-negative breast cancer. Moreover, AR-positive breast cancer has better clinicopathological features than AR-negative breast cancer, especially in the ER-negative subtype. These results suggest that the role of AR in ER-negative breast cancer is distinctive from that in ER-positive breast cancer.
BibTeX
@article{long2022ar,
  author = {Mengping Long and Chong You and Qianqian Song and Lina X. J. Hu and Zhaorong Guo and Qian Yao and Wei Hou and Wei Sun and Baosheng Liang and Xiao‐Hua Zhou and Yiqiang Liu and Taobo Hu},
  title = {{AR Expression Correlates with Distinctive Clinicopathological and Genomic Features in Breast Cancer Regardless of ESR1 Expression Status}},
  journal = {International Journal of Molecular Sciences},
  year = {2022},
  doi = {10.3390/ijms231911468},
}
Figure